Presse, Media and Investor Relations


Public relations

Only open exchange and dialogue can make change possible. We are always open for questions about us, medical cannabis, and the broad possibilities of phytopharmacological research. Any questions related to regulatory affairs and all questions by regulatory authorities should be directed to

Press Releases

October 4 2019: btov and Single Family Office Invest in German Cannabis: 7 Million Euros for DEMECAN

Pressemitteilung (German)
Pressemitteilung (English)

May 27 2019: DEMECAN confirming award for German medical cannabis production

Press release (German)
Press release (English)

December 20 2018: DEMECAN Pharma Signs 10.000 kg Supply Agreement

DEMECAN Pharma has signed a supply agreement with the Canadian licensed medical cannabis producer Invictus MD of 10.000 kg cannabis flowers for the duration of 5 years. More information can be found here.

Press about DEMECAN

May 20 2019: DEMECAN receives final approval to produce medical cannabis in Germany.
DEMECAN has been selected among 79 competitors by the German Bundesinstitut für Arzneimittel und Medizinprodukte BfArM (Federal Institute for Drugs and Medical Devices) as one of three companies to produce medical cannabis in Germany. In this competitive public tender that began July 2018, DEMECAN was awarded three of 13 possible lots, totaling at least 2400 kg over a period of 4 years. Selection criteria were mainly based on quality concepts for the production of cannabis that adhere to highest pharmaceutical standards. The cannabis produced by DEMECAN will be directly distributed to pharmacies by the German government.
Official BfArM press release (German)
Handelsblatt (German)
MJ Business

April 4th 2019: The German Cannabis agency announces their intend to award DEMECAN a cultivation license.
Handelsblatt (German)
Wallstreet Online (German)
MJBiz Daily
Deutsche Welle (German)

Press contact

For any press and media related questions, please contact

Investor Relations

If you are interested in collaborations or investment opportunities into DEMECAN, write us at